Where does Ascendis Pharma Endocrinology Division A/S rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ascendis Pharma Endocrinology Division A/S ranks #25,791 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ascendis Pharma Endocrinology Division A/S hold?

Ascendis Pharma Endocrinology Division A/S holds 10 US utility patents granted between 2018 and 2025, spanning 6 technology areas.

What is Ascendis Pharma Endocrinology Division A/S's Innovation Score?

Ascendis Pharma Endocrinology Division A/S has an Innovation Score of 33.3 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ascendis Pharma Endocrinology Division A/S focus on?

Ascendis Pharma Endocrinology Division A/S's top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 10 patents, ranking #2,196 of 7,163 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Ascendis Pharma Endocrinology Division A/S's patent grant rate increasing or decreasing?

Ascendis Pharma Endocrinology Division A/S's recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Ascendis Pharma Endocrinology Division A/S's patents?

Ascendis Pharma Endocrinology Division A/S's patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ascendis Pharma Endocrinology Division A/S

Q: How is the Ascendis Pharma Endocrinology Division A/S patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ascendis ranks #25,791 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 6 technology areas.

#25,791
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.3/100): 19.8
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R25791 · Foreign Corporation #25,791 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #25,791/49,997
PHOTO-FINISH Arrow Acquisition
CPC-NARROW A61K · 6 areas
INNOV-THIN 33.3/100
CLAIMS-RICH 19.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arrow Acquisition, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ascendis’s 33.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (25%) Velocity 4.4 pts (13%) Breadth 8.7 pts (26%) Claim depth 11.9 pts (36%)

Qualcomm Incorporated · highest

85
Ascendis Pharma… · this assignee

33
3D Lighting… · lowest

7

What this shows Ascendis's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ascendis?

Each dot is one of Ascendis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ascendis’s own 19.8 claims/patent is ABOVE the 11.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ascendis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ascendis's grants concentrate

Ascendis Pharma Endocrinology Division A/S is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2021. By volume, Ascendis sits between Arrow Acquisition, LLC and ATL Technology, LLC.

Ascendis's three-year grant acceleration

Ascendis Pharma Endocrinology Division A/S shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Arrow Acquisition

10
Artic Investments

10
Arzneimittel Apot…

10
AS Strömungstechn…

10
Ascendo Medienage…

10
Asymchem Laborato…

10
Athabasca OIL

10
ATL Technology

10
Ascendis Pharma E… ◀

10

What this shows Ascendis holds 10 patents at rank #25,713, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ascendis

By rank, the assignees closest to #25,713 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Ascendis's primary technology class.

Ascendis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Ascendis Pharma Endocrinology Division A/S patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	20.0%
2020	2	20.0%
2021	1	10.0%
2024	2	20.0%
2025partial year	3	30.0%

Which technologies does Ascendis Pharma Endocrinology Division A/S patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

C07K - Peptides 3

A01G - HORTICULTURE; Cultivation OF Vegetables, Flowers, Rice, Fruit, Vines, Hops OR SEAWEED; FORESTRY; Watering 2

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ascendis Pharma Endocrinology Division A/S's patent record in context - here's where to go next.

Ascendis Pharma Endocrinology Division A/S's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #25,791 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ascendis Pharma Endocrinology Division A/S against Arrow Acquisition, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.